HCV structural proteins interfere with interferon-alpha Jak/STAT signalling pathway

Antiviral Research

Volumn 76, Issue 2, 2007, Pages 194-197

  Luquin, Esther ^a   Larrea, Esther ^a   Civeira, Maria P ^b   Prieto, Jesús ^a,b   Aldabe, Rafael ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

HCV; Interferon; Interferon stimulated genes; Replicon; STAT phosphorylation

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; GAMMA INTERFERON; JANUS KINASE; RIBAVIRIN; STAT PROTEIN; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STRUCTURAL PROTEIN; VIRUS PROTEIN;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; REPLICON; SIGNAL TRANSDUCTION; VIRUS GENOME; VIRUS TRANSCRIPTION;

CELL LINE; DOWN-REGULATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HEPACIVIRUS; HUMANS; IMMUNOBLOTTING; INTERFERON-ALPHA; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; VIRAL NONSTRUCTURAL PROTEINS; VIRAL STRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 34548648264     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2007.06.004     Document Type: Article

References (23)

1. Blindenbacher A., Duong F.H.T., Hunziker L., Stutvoet S.T.D., Wang X., Terracciano L., Moradpour D., Blum H.E., Alonzi T., Tripodi M., La Monica N., and Heim M.H. Expression of hepatitis C virus proteins inhibits interferon-α signaling in the liver of transgenic mice. Gastroenterology 124 (2003) 1465-1475
2. Bode J.G., Ludwig S., Ehrhardt C., Erhardt A., Albrecht U., Schaper F., Heinrich P.C., and Haussinger D. IFN-α; antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J. 17 (2003) 488-490
3. Breiman A., Grandvaux N., Lin R., Ottone C., Akira S., Yoneyama M., Fujita T., Hiscott J., and Meurs E.F. Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKKepsilon. J. Virol. 79 (2005) 3969-3978
4. Chen L., Borozan I., Feld J., Sun J., Tannis L.-L., Coltescu C., Heathcote J., Edwards A.M., and McGilvray I.D. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128 (2005) 1437-1444
5. de Lucas S., Bartolomé J., and Carreño C. Hepatitis C virus core protein down-regulates transcription of interferon-induced antiviral genes. J. Infect. Dis. 191 (2005) 93-99
6. Duong F.H.T., Christen V., Berke J.M., Penna S.H., Moradpour D., and Heim M.H. Upregulation of protein phosphatase 2Ac by hepatitis C virus modulates NS3 helicase activity through inhibition of protein arginine methyltransferase 1. J. Virol. 79 (2005) 15342-15350
7. Duong F.H.T., Filipowicz M., Tripodi M., La Monica N., and Heim M.H. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology 126 (2004) 263-277
8. Gale J.M.J., Korth M.J., Tang N.M., Tan S.-L., Hopkins D.A., Dever T.E., Polyak S.J., Gretch D.R., and Katze M.G. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230 (1997) 217-227
9. Gao B., Hong F., and Radaeva S. Host factors and failure of interferon-α treatment in hepatitis C virus. Hepatology 39 (2004) 880-890
10. He X.-S., Ji X., Hale M.B., Cheung R., Ahmed A., Guo Y., Nolan G.P., Pfeffer L.M., Wright T.L., Risch N., Tibshirani R., and Greenberg H.B. Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. Hepatology 44 (2006) 352-359
11. Heim M.H., Moradpour D., and Blum H.E. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. J. Virol. 73 (1999) 8469-8475
12. Larrea E., Aldabe R., Molano E., Fernandez-Rodriguez C.M., Ametzazurra A., Civeira M.P., and Prieto J. Altered expression and activation of signal transducers and activators of transcription (STATs) in hepatitis C virus infection: in vivo and in vitro studies. Gut 55 (2006) 1188-1196
13. Li K., Foy E., Ferreon J.C., Nakamura M., Ferreon A.C.M., Ikeda M., Ray S.C., Gale Jr. M., and Lemon S.M. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 2992-2997
14. Lin W., Choe W.H., Hiasa Y., Kamegaya Y., Blackard J.T., Schmidt E.V., and Chung R.T. Hepatitis C virus expression suppresses interferon signaling by degrading STAT1. Gastroenterology 128 (2005) 1034-1341
15. Lin W., Kim S.S., Yeung E., Kamegaya Y., Blackard J.T., Kim K.A., Holtzman M.J., and Chung R.T. Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain. J. Virol. 80 (2006) 9226-9235
16. Lohmann V., Körner F., Koch J.O., Herian U., Theilmann L., and Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285 (1999) 110-113
17. Manns M.P., Wedemeyer H., and Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55 (2006) 1350-1359
18. Meylan E., Curran J., Hofmann K., Moradpour D., Binder M., Bartenschlager R., and Tschopp J. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437 (2005) 1167-1172
19. Platanias L.C. Mechanisms of type-I and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5 (2005) 375-386
20. Rebouillat D., and Hovanessian A.G. The human 2′,5′-oligoadenylate synthetase family: interferon-induced proteins with unique enzymatic properties. J. Interferon Cytokine Res. 19 (1999) 295-308
21. Shepard C.W., Finelli L., and Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5 (2005) 558-567
22. Taylor D.R., Shi S.T., Romano P.R., Barber G.N., and Lai M.M. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285 (1999) 107-110
23. Thimme R., Lohmann V., and Weber F. A target on the move: innate and adaptive immune escape strategies of hepatitis C virus. Antiviral Res. 69 (2006) 129-141